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Purpose—Doctor-patient communication is the primary way women diagnosed with breast 
cancer learn about their risk of distant recurrence. Yet little is known about how doctors approach 
these discussions.
Methods—A weighted random sample of newly diagnosed early stage breast cancer patients 
identified through SEER registries of Los Angeles and Georgia (2013–2015) were sent surveys 
~about 2 months after surgery (Phase 2, N=3930, RR 68%). We assessed patient perceptions of 
doctor communication of risk of recurrence (i.e., amount, approach, inquiry about worry). 
Clinically-determined 10-year risk of distant recurrence was established for low and intermediate 
invasive cancer patients. Women’s perceived risk of distant recurrence (0–100%) was categorized 
into subgroups: overestimation, reasonably accurate, zero risk. Understanding of risk and patient 
factors (e.g., health literacy, numeracy and anxiety/worry) on physician communication outcomes 
was evaluated in multivariable regression models (analytic sample for substudy = 1295).
Results—About 33% of women reported doctors discussed risk of recurrence “quite a bit” or “a 
lot” while 14% said “not at all.” Over half of women reported doctors used words and numbers to 
describe risk, while 24% used only words. Overestimators (OR =.50, CI 0.31, 0.81) or those who 
perceived zero risk (OR =.46, CI 0.29,0.72) more often said their doctor did not discuss risk. 
Patients with low numeracy reported less discussion. Over 60% reported their doctor almost never 
inquired about worry.
Conclusions—Effective doctor-patient communication is critical to patient understanding of risk 
of recurrence. Efforts to enhance physicians’ ability to engage in individualized communication 
around risk are needed.
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Introduction
Systemic recurrence of breast cancer is the most feared outcome after the diagnosis of early 
stage breast cancer. Understanding personal risk of recurrence and its implications for 
treatment decisions and survivorship care is challenging for many women diagnosed with 
breast cancer. Several studies have found that a considerable number of women overestimate 
their risk of distant recurrence after treatment [1,2], while others underestimate their risk [1]. 
The question is, how important is it for women to have a reasonably accurate understanding 
of their risk of distant recurrence?
A growing body of research suggests that misconceptions about risk are associated with less 
desirable behavior and health outcomes. Overestimation has been associated with preference 
for more extensive treatment than necessary [2], greater ongoing worry [3], a hypervigilance 
about symptoms resulting in unscheduled visits [4,5] and worse quality of life [1]. In 
contrast, underestimation may lessen one’s commitment to surveillance recommendations 
regarding mammography [6–8] and/or adhering to endocrine therapy [9].
Most breast cancer patients want to know about their risk of recurrence [10,11], and many 
desire more information than they currently receive [10,12,13]. Although doctor-patient 
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communication is the primary way women with breast cancer learn about their risk, few 
studies have examined patient perceptions of how often doctors discuss risk and what 
approach is used in these discussions [14–16]. Importantly, in our previous study most 
surgeons and medical oncologists report they discuss risk with their patients [16]. There is 
no clear consensus on which approach to communicating risk yields greater patient 
understanding [15,17–19], although most patients favor a simplied format rather than a more 
complex report [15,20].
Effective shared decision-making can only be achieved if breast cancer patients understand 
their recurrence risk and how various treatments might influence it [16]. For some women, 
these discussions may be particularly challenging and require additional time and/or 
personalized approaches based on individual factors [21–23]. For example, less numerate 
women may require presentation of risk using formats that do not depend solely on numbers 
[19,24,25]. Women with low health literacy find discussions about risk challenging but are 
less likely to ask questions [23,26,27]. Unfortunately, many studies to date evaluating 
approaches to presenting risk information are limited by relatively small, non-diverse patient 
samples.
In addition, general anxiety about the cancer diagnosis and/or more specific worry about 
cancer recurrence have been associated with greater inaccuracy in perceived risk of 
recurrence [10,11,28]. Worry about recurrence has been found to influence decisions in 
favor of more extensive surgery, such as CPM, even though there is no evidence that the 
procedure reduces systemic recurrence [2,21]. What needs further study is whether doctor-
patient communication about risk of recurrence varies among more vulnerable patient 
subgroups.
To address these gaps, this paper has three major objectives: (1) to characterize patients’ 
perceptions of doctor-patient discussions about risk of recurrence in a large, diverse 
population-based sample of women with early stage invasive breast cancer, (2) to determine 
if the amount of discussion, approach used, and/or assessment of worry during the 
communication effort are associated with patient understanding of risk, and (3) to determine 




The iCanCare Study, a large, diverse, population-based survey study of women with 
favorable prognosis breast cancer, accrued women ages 20–79 with newly diagnosed breast 
cancer (DCIS and stages I–II) as identified by rapid reporting systems from the Surveillance 
Epidemiology and End Results (SEER) registries of Georgia and Los Angeles County from 
July 2013 to August 2015. Black, Asian, and Hispanic women were oversampled in Los 
Angeles [29]. In Phase 2 of the study, we selected 3930 women of whom 258 women were 
later deemed ineligible due to a prior cancer diagnosis or stage III or IV disease; residing 
outside the SEER registry area; or being deceased, too ill or unable to complete a survey in 
Spanish or English. Of the 3672 eligible women, 2502 (68%) patients responded, and 1172 
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did not return mailed surveys or refused to participate. Of 2502 women, 1207 did not meet 
eligibility criteria for this sub-study: 444 had DCIS, 555 had a clinically estimated 
recurrence risk higher than our definition for “intermediate risk invasive,” and 141 had 
insufficient data to calculate risk. The resulting analytic sample was 1295 women.
Data Collection
Patients were sent surveys approximately 2 months after surgery. The median time between 
surgical path and receipt of the survey was 8 months. We provided a $20 cash incentive and 
used a modified Dillman method for patient recruitment, as done in prior work [29,30]. All 
materials were sent in English and Spanish to those with Spanish surnames [29]. Survey 
responses were merged with clinical data from SEER. The study was approved by the 
Institutional Review Boards of the University of Michigan, University of Southern 
California and Emory University and the Committee for the Protection of Human Subjects 
and the California Cancer Registry.
Questionnaire Design and Content
Patient questionnaire content was guided by a conceptual framework, research questions, 
and hypotheses. We chose established measures when available and developed new 
measures, when necessary, drawing from the literature and our prior research [31–33]. We 
used standard techniques to assess content validity, including expert review, cognitive pre-
testing, and pilot studies in clinic populations.
Measures
Primary outcome: The doctor-patient communication items regarding risk included: (1) 
how much your doctor discussed risk of recurrence (5-pt Likert scale, “not at all” to “a lot”), 
(2) if the discussion included words only, numbers only, or both, and (3) how often the 
doctor asked about worry about the cancer coming back (5-pt Likert scale, “almost never” to 
“almost always”).
Primary correlates: The primary correlates included patient perceived risk of systemic 
recurrence and personal factors known to influence understanding of risk (i.e., numeracy, 
health literacy, general worry, worry about recurrence).
Patient perceived risk of recurrence
Determining actual risk of systemic recurrence: From the analytic sample for women 
with invasive disease, we classified women as having relatively “low actual risk” (<10%) or 
“intermediate actual risk” (<20%) of distant recurrence, using stage, histology and biology. 
Using SEER, actual risk was estimated following treatment (surgery, radiation, 
chemotherapy). Women were classified as low risk if SEER data indicated stage IA, ER+, 
HER2-, tumor grade 1–2, and Oncotype DX either not done or recurrence score 0–10. 
Women were classified as intermediate risk if SEER data indicated stage IA, ER+, HER2−, 
tumor grade 1–2, and Oncotype DX recurrence score >10; or stage IA, ER+, HER2−, and 
tumor grade 3+; or stage IB or IIA, ER+, HER2−, with any tumor grade and any Oncotype 
DX status.
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Patients’ perceived risk of systemic recurrence: Women were asked to give a numeric 
estimate from 0 to 100: “After receiving all the planned treatments, what do you think is the 
chance that your cancer will spread to other parts of your body in 10 years?”. For women 
with “low-risk” invasive cancer, overestimation was defined as 20% or higher. For women 
with “intermediate-risk” invasive, overestimation was defined as 30% or higher. These 
percent cutoffs were chosen by clinical experts to represent “substantial overestimation” of 
risk of recurrence as they were considerably higher than the “clinically estimated risk” of 
systemic recurrence expected following treatment for these patients with favorable prognosis 
[34,35]. For all women with invasive disease, if they indicated that the chance of their cancer 
spreading to other parts of their bodies was 0%, we considered them to perceive “zero risk” 
of recurrence.
Numeracy and health literacy—Numeracy was assessed with an item: “How often do 
you find numerical information to be useful” (5-pt scale “never” to “very often”) [36,37]. 
Health literacy was measured by an item: “How often do you have someone help you when 
you read instructions, pamphlets, or other written material from your doctor or pharmacy” 
(5-pt scale “never” to “always”) [38,39].
General worry and worry about recurrence—The “general worry” measure asked 
women on a scale from 1–10, “all things considered, I feel that I almost never worry” to 
“almost always worry.” Worry specific to breast cancer recurrence was assessed by asking 
women, “in the past month, how often have you worried about your cancer coming back” (5-
pt scale “almost never” to “almost always”) [11].
Additional Covariates
Sociodemographic covariates included age, race/ethnicity (White, Black, Latina, Asian, 
Other/Unknown), educational attainment (high school graduate or less, some college or 
more), and family history of breast cancer (none vs. >1 first degree relative). Clinical 
covariates included SEER stage, recurrence risk group, breast cancer treatment 
(lumpectomy; unilateral mastectomy; bilateral mastectomy), receipt of radiation (yes/no), 
receipt of chemotherapy (yes/no), and presence of comorbid health conditions (none vs. 
>1) .
Statistical Analyses
First, we calculated descriptive statistics on the distribution of patient factors and doctor-
patient communication measures. We then fit multivariable regression models to the three 
doctor-patient communication outcomes: 1) whether the doctor discussed risk of cancer 
recurrence (yes/no); 2) the approach used to discuss risk (none/words only/numbers only/
both); and 3) whether the doctor asked the patient about worry about recurrence (almost 
never vs at least some). Patient understanding of systemic recurrence risk was categorized as 
(zero risk/reasonably accurate/overestimation) compared to clinically estimated risk. To 
examine whether each patient “personal” factor is an independent predictor of the first and 
third outcomes, we fit separate logistic regression models, while controlling for 
sociodemographic and clinical factors. To examine the association of the doctor-patient 
communication approach (none/words/numbers/both) with the accuracy of patient risk 
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perception (zero risk, reasonably accurate, overestimation), a generalized logit model was 
used, while adjusting for sociodemographic and clinical factors. Based on this model, a 
patient’s predicted probability for each reported communication approach was calculated for 
their respective risk perception group when assuming site of Emory, age < 50, white, no 
college, no family history of breast cancer, no comorbidities, low clinically estimated risk of 
recurrence, stage I, no radiation or chemotherapy, and lumpectomy treatment). As a 
sensitivity analysis, a linear regression was performed to examine whether the amount of 
physician communication was associated with how accurately patients understood their risk 
of distant recurrence. All regression models adjusted for sociodemographic and clinical 
factors. All statistical analyses incorporate weights to account for differential probabilities of 
sample selection and non-response. Weighting allows statistical inferences to be more 
representative of the target population and reduces potential bias due to non-response. All 
analyses used SAS software, Version 9.4 (SAS Institute, Cary, NC).
RESULTS
Table 1 presents the sample characteristics. Approximately 86% of patients were over the 
age of 50, 38% were non-white, 69% had achieved some college education, and 76% had no 
family history of breast cancer. With regard to clinical factors, 75% were SEER stage I, 67% 
had a lumpectomy, 64% had radiation therapy, and 18% had chemotherapy. About 27% of 
patients reported “zero risk” of distant recurrence while 21% overestimated their risk. About 
one quarter (24%) of women reported at least sometimes needing help with written material, 
and 17% reported low numeracy. In terms of worry, about 61% reported they considered 
themselves “worriers” at least some of the time, and about 37% reported they worried 
specifically about cancer recurrence from “sometimes” to “almost always.”
Figure 1 demonstrates the distribution of the doctor-patient communication measures about 
risk. With regard to how much their doctor discussed the chance of cancer coming back, 
33% reported “quite a bit” or “a lot,” 14% “not at all,” and 26% responded “a little bit.” In 
terms of how the doctor discussed risk, 24% of patients reported their doctor used “only 
words,” 11% said “only numbers,” and 51% reported their doctor used “both words and 
numbers.” Over 60% of patients reported their doctors “almost never” asked of worry about 
recurrence, with an additional 24% responding “rarely.”
Figure 2 displays the association between each primary patient correlate and patients’ 
perception of whether their doctor discussed risk of recurrence. Specifically, patients who 
overestimated their risk and those who perceived zero risk of recurrence were were 
significantly less likely to report having had any kind of discussion with their doctors about 
risk [OR=0.50 (0.31, 0.81) for overestimation; OR=0.46 (0.29, 0.72) for zero risk]. When 
we looked more specifically at whether how much the doctor discussed risk mattered, the 
linear regression showed that more discussion was significantly associated with more 
patients having reasonable accuracy of distant recurrence risk (vs. not). Patients who 
reported low numeracy also reported less discussion around cancer recurrence [OR=0.64 
(0.43, 0.95)]. Other personal factors (e.g., health literacy and/or patient worry) were not 
significantly associated with patient perception of whether their doctor discussed recurrence 
risk.
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Figure 3 displays the predicted probability of physicians using each approach to discuss risk 
with their patients according to the accuracy of patients’ risk perception. Patients who had 
misperceptions about their risk of recurrence were more likely to report that their physicians 
did not discuss cancer recurrence at all, and less likely to report their physicians discussed 
risk using “both words and numbers” or “only numbers.” Note that among patients who had 
a reasonably accurate understanding of their numeric risk, only 4% reported that their doctor 
did not discuss risk, while 73% said their doctor used either “numbers only” or “both words 
and numbers.”
Figure 4 shows the relationship between each primary correlate and patient perception of 
whether their doctor asked about worry concerning the cancer coming back. While patients 
who overestimated their cancer risk showed no association with the doctor asking about 
worry of recurrence, patients whose perceived risk was zero were significantly more likely 
to report that their physician almost never asked about worry [OR=0.58 (0.42, 0.81)]. 
Patients who reported some general worry were more likely to report their doctor asking 
about worry, though this was not significant for patients who reported almost always worry. 
Similarly, respondents who worried specifically about recurrence at least sometimes were 
significantly more likely to report that their physicians asked about worry [OR=2.31 (1.75, 
3.05)]. While not statistically significant, patients who had low health literacy were more 
likely to report that their doctors asked about worry [(OR=1.24 (0.89, 1.72)].
DISCUSSION
In this large, diverse, population-based sample of newly diagnosed women with invasive 
breast cancer, patients’ perceptions of how often their physicians communicated about 
systemic recurrence risk were associated with the accuracy of patients’ perception of risk. 
Women who perceived they had zero risk of recurrence or overestimated their risk were less 
likely to report discussions of risk. Almost 15% of women reported their doctor never 
discussed risk, and these women were the least likely to have a reasonable understanding of 
their numeric recurrence risk. Given the negative outcomes associated with misperceptions 
about risk [7,40], our findings substantiate the importance of doctor-patient communication 
efforts around risk of recurrence as it relates to decisions about treatment and breast cancer 
survivorship behaviors. Patients who overestimate their risk may be more vulnerable to 
pursuing aggressive testing and treatment even when there is no evidence-based rationale for 
such choices [2,7,21]. In addition, women who perceive no chance of recurrence may be less 
likely to adhere to survivorship recommendations including symptom surveillance, regular 
follow-up, and adjuvant endocrine therapy that plays an essential role in reducing distant 
recurrence risk [6–9].
The approach used by physicians to describe risk was also associated with patients’ level of 
understanding of numeric risk. Among those who had a reasonably accurate understanding 
of their numeric risk of distant recurrence, almost two thirds (64%) reported that their doctor 
used a combination of words and numbers, while only 23% of these women reported the 
doctor used only words. While the advantages of verbal communication include that it 
allows for easier and more natural discussion about risk and may better capture a person’s 
emotions [17], the disadvantage is the variability inherent in interpretation of terms such as 
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“unlikely,” “rare,” “low risk” [17]. Numeric communication has the appeal of more 
precision, and providing a standard of reference, but needs to be supplemented with other 
representations, particularly for women with low numeracy [19]. Overall, these findings 
suggest that for women to understand their numeric risk, some combination of words and 
numbers may present the most ideal approach. Note that in our previous study, 88% of 
medical oncologists compared to 47% of surgeons reported using numerical estimates when 
discussing risk [16].
This study also assessed whether doctor-patient communication varied by patient factors 
known to make some discussions more challenging. Women with low numeracy were less 
likely to report physicians’ discussions about risk of recurrence. Previous studies have 
demonstrated that low numeracy is a predictor of lower comprehension of risk [37] and 
recommend spending additional time with low numerate patients explaining risks and 
benefits [41] and using risk presentation formats that are easier to evaluate in order to reduce 
the amount of cognitive effort involved [42–44]. Risk communication strategies might 
include verbal translations and/or graphical displays along with numbers to increase the 
likelihood of understanding these messages [45]. Unfortunately, we did not find that women 
with low health literacy received any more communication about risk than those with higher 
literacy. Previous studies suggest that women with low health literacy express more unmet 
information needs [46], and may benefit from strategies such as encouraging question 
asking, or using “teach back” techniques (asking patients to describe what they just heard in 
their own words) [47,48].
Even though anxiety and worry have been associated with misperceptions of risk [28], a 
majority (60%) of patients reported that physicians “almost never” asked if they were 
worried about recurrence. Anxiety and worry about recurrence definitely influence women 
during the treatment decision-making process [49], and well into survivorship [11]. Whether 
correction of risk estimates alone will result in less worry is uncertain [14]. In a Cochrane 
review (2013) on the value of personalized risk communication, the authors concluded that 
incorporating personalized risk estimates increases knowledge, may increase accuracy of 
risk and enhance informed choices, but may not significantly affect an individual’s anxiety 
[14,50]. However, identifying women who are anxious or worry about recurrence and 
simultaneously managing their worry with supportive care while correcting misconceptions 
about recurrence risk seems like a reasonable approach [21,24,51]. Our findings do suggest 
that physicians are more likely to inquire about worry among women who themselves report 
the most worry. Notably, many oncologists and surgeons report lack of confidence in 
managing worry about recurrence with their patients [12,24].
Further studies might focus on physician education and skill building in risk communication 
and management of worry [52]. Evaluation of innovative physician education interventions 
that employ multiple modes of delivery (web and face-to-face) as well as multi-faceted 
approaches (e.g., modeling, framing of risk, feedback [50,53]), are needed to identify best 
practices in communication of health risk across diverse populations. Further research 
involving patients might focus on better understanding of factors that influence women’s 
perceptions of risk, and the mistakes they make when evaluating their personalized 
vulnerability regarding recurrence [40]. Supplementing physician communication with 
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patient decision tools as well as utilizing other medical personnel in the communication 
process seem like promising directions [14,19,50]. Longitudinal studies are also needed to 
monitor whether survivor behaviors vary over time among women who overestimate their 
risk or perceive zero risk of recurrence.
Strengths of this study include a large, diverse sample, clinical information to determine 
actual recurrence risk, a high participation rate, and use of weighting. However, the study 
has some limitations. Doctor-patient communication around risk was captured with patient 
perceptions and is subject to recall. The communication measures asked about “your 
doctors” and did not capture risk discussions by other health care personnel. In addition, we 
did not have an “uncertain” or “don’t know” category in our numeric risk items [1]. Patients 
lived in two geographic regions, so findings may not represent all U.S. breast cancer 
patients. Although we had detailed clinical information from SEER to determine actual risk, 
it is possible that patients perceived additional factors influencing their risk that were not 
assessed. Finally, associations observed in the study are not necessarily causal.
IMPLICATIONS
Risk of systemic cancer recurrence is a difficult concept to communicate to patients 
particularly in the emotionally charged setting of a new cancer diagnosis [10]. Our results 
emphasize the importance of doctor-patient communication about risk and suggest further 
strategies that may improve patient understanding. Physicians should communicate risk 
information using a combination of approaches, usually including both words and numbers, 
and possibly supplemented with easy-to-understand written materials. Assessing patient 
numeracy may be helpful, and developing communication strategies that low numerate 
patients can understand would likely be a valuable starting point for discussions of 
recurrence risk with most patients. In addition, assessing anxiety and worry across the care 
trajectory from diagnosis through survivorship may identify women who would benefit from 
supportive services to manage worry. Further studies need to test additional strategies to 
communicate risk to vulnerable and diverse populations. Physicians must be sensitive to 
personal characteristics of their patient population in deciding on approaches and formats 
used to communicate risk.
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Figure 2. Association Between Each Primary Patient Correlate and Patients’ Perception of 
Whether Their Doctor Discussed Risk of Recurrence
Footnote: (Ref = ‘Not at All’) A separate logistic regression model is fit for each patient 
correlate, while controlling for age, race/ethnicity, educational attainment, and family history 
of breast cancer, SEER stage, recurrence risk group, breast cancer treatment, receipt of 
radiation, receipt of chemotherapy, and presence of comorbid health conditions
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Figure 3. Predicted Probability of Doctors Using Various Approaches When Discussing Risk 
According to Patients’ Understanding of their Risk of Recurrence
Footnote: A generalized logit model was used to examine the association of the doctor-
patient communication approach (none/words/numbers/both) with the accuracy of patient 
risk perception (zero risk, reasonably accurate, overestimation), while adjusting for 
sociodemographic and clinical factors. Based on this model, a patient’s predicted probability 
for each reported communication approach was calculated for their respective risk 
perception group when assuming site of Emory, age < 50, white, no college, no family 
history of breast cancer, no comorbidities, low clinically estimated risk of recurrence, stage 
I, no radiation or chemotherapy, and lumpectomy treatment
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Figure 4. Association Between Each Primary Correlate and Patient Perception of Whether Their 
Doctor Asked if They Were Worried About Their Cancer Coming Back
Footnote: (Ref = ‘Almost Never’) A separate logistic regression model is fit for each patient 
correlate, while controlling for age, race/ethnicity, educational attainment, and family history 
of breast cancer, SEER stage, recurrence risk group, breast cancer treatment, receipt of 
radiation, receipt of chemotherapy, and presence of comorbid health conditions
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Table 1




 Under 50 14
 50–65 43
 65 and over 43
Race
 Asian 9
 Non-Hispanic White 60
 Non-Hispanic Black 15
 Latina 14
Education
 High School Diploma or Less 29
 Some college or more 69
Family History
 No family history of BRCA 76







 Unilateral mastectomy 16









 1 or more 31
Patient factors-Manageable
Understanding recurrence risk
 Zero risk 27
 Reasonably accurate 51
 Overestimation 21
Health Literacy (needs help with written materials)


















Numeracy (finds numbers useful)
 Never/Rarely 17
 Sometimes 40
 Often/Very Often 40
Worry in general
 Almost never worry 38
 Sometimes worry 43
 Almost always worry 18
Worry about recurrence
 Almost Never/Rarely 60
 Sometimes 24
 Often/Almost Always 13
Note:
*
these percentages do not add up to 100% due to missingness.
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